Published Technical Disclosure Archive

Specialized Medium Chain Triglyceride Compositions for Extreme Environments

Publication ID: 24-11857527_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Medium Chain Triglyceride Compositions for Extreme Environments,” Published Technical Disclosure No. 24-11857527_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857527_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,527.

Summary of the Inventive Concept

The present inventive concept relates to novel medium chain triglyceride (MCT) compositions and systems tailored for specific, narrow markets or unique operational environments, such as high-security needs, disaster relief, or extreme weather conditions.

Background and Problem Solved

The original patent disclosed MCT compositions for general brain energy deficiency conditions or diseases and neurological conditions. However, these compositions may not be suitable for extreme environments where specific requirements and constraints apply. The present inventive concept addresses this limitation by providing MCT compositions and systems adapted for these niche markets.

Detailed Description of the Inventive Concept

The inventive concept comprises MCT compositions with specific ratios of MCT-C8 to MCT-C10, such as 30:70 to 70:30 (mol/mol), and at least 95 mol % of MCT-C8 and MCT-C10. These compositions are designed for emergency nutrition in extreme weather conditions, high-security environments, disaster relief, and remote or isolated areas. The systems may include means for administering the composition to an individual, such as hermetically sealed containers or thermally insulated containers.

Novelty and Inventive Step

The novelty of the present inventive concept lies in the adaptation of MCT compositions for specific, narrow markets or unique operational environments, which is not addressed by the original patent. The inventive step resides in the selection of specific ratios and purities of MCT-C8 and MCT-C10, as well as the design of systems tailored for these niche markets.

Alternative Embodiments and Variations

Alternative embodiments may include MCT compositions with different ratios of MCT-C8 to MCT-C10, or the use of additional MCTs with different chain lengths. Variations may also include different packaging or administration means, such as single-serve packets or oral sprays.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the markets of emergency nutrition, high-security environments, disaster relief, and remote or isolated areas. The target industries may include food and beverage, pharmaceuticals, and defense.

Field of Art

Nutritional biochemistry and medical compositions, specifically focused on medium-chain triglyceride (MCT) formulations for neurological and metabolic applications

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in biochemistry or nutrition science, familiar with lipid composition techniques, medical formulation strategies, and nutritional intervention design

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's MCT composition teachings, merely adapting the established MCT-C8 and MCT-C10 formulation to specific environmental and nutritional delivery contexts. The core chemical composition remains substantially unchanged, with only packaging and application context modified. The fundamental MCT ratio and molecular structure principles established in the source patent directly enable the PTD's proposed variations.

Obvious Combinations & Variations

Source Patent Element
MCT composition with specific ratios of MCT-C8 and MCT-C10
PTD Variation
Adjusting MCT ratio to 30:70 to 70:30 (mol/mol) for specialized environments
Obviousness Reasoning
Predictable variation within known compositional ranges, representing routine optimization of existing MCT formulation parameters
Source Patent Element
Method of administering MCT compositions for neurological conditions
PTD Variation
Developing specialized delivery systems like hermetically sealed containers for extreme environments
Obviousness Reasoning
Known packaging technique for preserving nutritional compositions, representing standard design choice for protecting sensitive medical formulations
Source Patent Element
MCT composition targeting brain energy metabolism
PTD Variation
Adapting composition for emergency nutrition and disaster relief scenarios
Obviousness Reasoning
Logical extension of existing nutritional intervention strategy, applying established MCT principles to novel contextual requirements
Source Patent Element
Composition comprising at least 98 mol% MCT-C8 and MCT-C10
PTD Variation
Slightly modifying purity to 95 mol% for specialized applications
Obviousness Reasoning
Minor compositional adjustment within predictable technical parameters, representing routine formulation optimization
35 U.S.C. § 103 Summary: Based on US Patent 11857527's comprehensive teachings regarding medium-chain triglyceride compositions, the present published technical disclosure would render obvious to a person having ordinary skill in the art any subsequent patent claims involving specialized MCT formulations for environmental or nutritional intervention contexts, as the core compositional principles and molecular strategies are directly derived from and predictably extended by the foundational source patent.

Original Patent Information

Patent NumberUS 11,857,527
TitleMedium chain triglyceride compositions
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.